Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : SPY Advance - Decline data for 2014 through 2016 -- Ignore unavailable to you. Want to Upgrade?

To: rimshot who wrote (163)	11/16/2020 10:06:43 AM
From: rimshot	Respond to of 1118

Moderna Inc. said Monday that its COVID-19 vaccine candidate met its primary endpoint in a Phase 3 trial, demonstrating 94.5% efficacy and requires only standard refrigeration , a far higher efficacy rate than originally expected Cambridge, Mass.–based Moderna MRNA, 6.46% said it plans to submit an emergency-use-authorization application with the U.S. Food and Drug Administration for the vaccine, which is named mRNA-1273, in the coming weeks and expects it to be based on the final analysis of 151 cases and a median follow-up of more than two months. The FDA has said it would require a coronavirus vaccine to be at least 50% effective to win approval. The Phase 3 trial enrolled more than 30,000 participants in the U.S. and is being conducted with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.